SOS1 Inhibition Suppresses the Emergence of Osimertinib Resistance to Generate a Durable Response in EGFR-Mutant Lung Cancer

The authors found that inhibiting the proximal receptor tyrosine kinase signaling intermediate SOS1 promoted continued osimertinib efficacy in sensitive cells and restored sensitivity in cells with acquired resistance.